US20130131192A1 - Composition, method, and kit for alpha-1 proteinase inhibitor - Google Patents

Composition, method, and kit for alpha-1 proteinase inhibitor Download PDF

Info

Publication number
US20130131192A1
US20130131192A1 US13/504,783 US201013504783A US2013131192A1 US 20130131192 A1 US20130131192 A1 US 20130131192A1 US 201013504783 A US201013504783 A US 201013504783A US 2013131192 A1 US2013131192 A1 US 2013131192A1
Authority
US
United States
Prior art keywords
composition
api
amino acid
alanine
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/504,783
Other languages
English (en)
Inventor
Jianxin Guo
Anthony Klos
Bret Coldren
Deborah Barnette
Mark Manning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols Therapeutics LLC
Original Assignee
Grifols Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43970713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20130131192(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Therapeutics LLC filed Critical Grifols Therapeutics LLC
Priority to US13/504,783 priority Critical patent/US20130131192A1/en
Publication of US20130131192A1 publication Critical patent/US20130131192A1/en
Assigned to DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT reassignment DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT SECURITY AGREEMENT Assignors: GRIFOLS INC., Grifols Therapeutics Inc., GRIFOLS-CHIRON DIAGNOSTICS CORP.
Assigned to GRIFOLS, S.A., TALECRIS BIOTHERAPEUTICS, INC., GRIFOLS INC. reassignment GRIFOLS, S.A. RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 26390/0193 Assignors: DEUTSCHE BANK AG NEW YORK BRANCH
Assigned to Grifols Therapeutics Inc., GRIFOLS DIAGNOSTIC SOLUTIONS INC., GRIFOLS SHARED SERVICES NORTH AMERICA INC. reassignment Grifols Therapeutics Inc. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: DEUTSCHE BANK AG NEW YORK BRANK
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
US13/504,783 2009-11-03 2010-11-02 Composition, method, and kit for alpha-1 proteinase inhibitor Abandoned US20130131192A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/504,783 US20130131192A1 (en) 2009-11-03 2010-11-02 Composition, method, and kit for alpha-1 proteinase inhibitor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25771109P 2009-11-03 2009-11-03
PCT/US2010/055135 WO2011056793A2 (en) 2009-11-03 2010-11-02 Composition, method, and kit for alpha-1 proteinase inhibitor
US13/504,783 US20130131192A1 (en) 2009-11-03 2010-11-02 Composition, method, and kit for alpha-1 proteinase inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/055135 A-371-Of-International WO2011056793A2 (en) 2009-11-03 2010-11-02 Composition, method, and kit for alpha-1 proteinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/926,450 Continuation US9616126B2 (en) 2009-11-03 2015-10-29 Composition, method, and kit for alpha-1 proteinase inhibitor

Publications (1)

Publication Number Publication Date
US20130131192A1 true US20130131192A1 (en) 2013-05-23

Family

ID=43970713

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/504,783 Abandoned US20130131192A1 (en) 2009-11-03 2010-11-02 Composition, method, and kit for alpha-1 proteinase inhibitor
US14/926,450 Active US9616126B2 (en) 2009-11-03 2015-10-29 Composition, method, and kit for alpha-1 proteinase inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/926,450 Active US9616126B2 (en) 2009-11-03 2015-10-29 Composition, method, and kit for alpha-1 proteinase inhibitor

Country Status (19)

Country Link
US (2) US20130131192A1 (es)
EP (1) EP2496246B1 (es)
JP (2) JP2013510158A (es)
KR (1) KR20120114235A (es)
CN (1) CN102655876B (es)
AU (1) AU2010315325B2 (es)
BR (1) BR112012010392B8 (es)
CA (1) CA2779369C (es)
CL (1) CL2012001159A1 (es)
ES (1) ES2679819T3 (es)
HU (1) HUE039240T2 (es)
IL (1) IL219485A (es)
MX (1) MX2012005132A (es)
NZ (1) NZ599783A (es)
PL (1) PL2496246T3 (es)
PT (1) PT2496246T (es)
RU (1) RU2555332C2 (es)
TR (1) TR201809898T4 (es)
WO (1) WO2011056793A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566031B2 (en) * 2019-03-04 2023-01-31 Tae Life Sciences, Llc Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140108516A (ko) * 2011-12-30 2014-09-11 그리폴스, 에스.에이. 폐 악화의 발현 또는 진행을 지연시키기 위한 알파1-프로테이나제 억제제
IL267520B2 (en) * 2016-12-22 2023-09-01 Kamada Ltd Dry powder composition of alpha-1 antitrypsin
WO2018132874A1 (en) * 2017-01-19 2018-07-26 Csl Limited Method of preventing an immune response with alpha- 1 anti-trypsin
IL267923B2 (en) 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
BR112022016234A2 (pt) 2020-02-25 2022-10-11 Grifols Worldwide Operations Ltd Método para obtenção de inibidor de proteinase alfa-1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940480A (en) * 1972-05-08 1976-02-24 Eisai Co., Ltd. Process for production of stabilized powdery secretin preparation by lyophilization
US20070020199A1 (en) * 1994-03-07 2007-01-25 Platz Robert M Dispersible macromolecule compositions and methods for their preparation and use
US20080261868A1 (en) * 1999-03-05 2008-10-23 Leland Shapiro Methods and Compositions for Treating Diabetes

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118819A (en) 1975-04-08 1976-10-19 Green Cross Corp:The A process for preparing heat stable antitrypsin
JPS597693B2 (ja) 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
US4337242A (en) 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4623717A (en) 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
DE3262575D1 (en) 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
US5218091A (en) 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
WO1986000337A1 (fr) 1984-06-19 1986-01-16 Transgene S.A. DERIVES DE L'alpha1-ANTITRYPSINE HUMAINE ET PROCEDE POUR LEUR PREPARATION
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE3901917A1 (de) 1989-01-24 1990-07-26 Behringwerke Ag Mutanten von humanem antithrombin iii
GB8913183D0 (en) 1989-06-08 1989-07-26 Central Blood Lab Authority Chemical products
US5079336A (en) 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5032405A (en) 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
JP3479539B2 (ja) 1992-04-10 2003-12-15 エーザイ株式会社 ヒトアンチトロンビンｉｉｉ変異体
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5561115A (en) 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
EP1079791A4 (en) 1998-05-12 2003-09-03 Susan C Bock HUMAN ANTITHROMBINS III AND RELATED METHODS
PT2130554E (pt) 1999-02-22 2012-11-19 Univ Connecticut Formulações de factor viii isentas de albumina
US20040157911A1 (en) 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US20030170813A1 (en) 2000-07-05 2003-09-11 Kenichi Suga Process for producing glycoprotein
US20050013867A1 (en) * 2001-10-19 2005-01-20 Lehrman S. Russ Use of proton sequestering agents in drug formulations
WO2003086451A1 (en) 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
CA2483102C (en) * 2002-04-25 2013-06-18 The Scripps Research Institute Treatment and prevention of pulmonary conditions
US7777006B2 (en) * 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
DE602004013021T3 (de) 2003-09-22 2012-04-05 Kamada Ltd. Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
AU2004290587B2 (en) 2003-11-14 2010-08-12 Arriva Pharmaceuticals, Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
WO2005049801A2 (en) 2003-11-14 2005-06-02 Arriva Pharmaceuticals, Inc. Dry protein formulation
BRPI0509117A (pt) 2004-03-04 2007-08-28 Wyeth Corp método de liofilização para melhorar a cristalização de excipientes
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
US20070237758A1 (en) 2005-11-22 2007-10-11 Anthony Barry Immunoglobulin fusion protein formulations
WO2007091266A2 (en) 2006-02-09 2007-08-16 Kamada Ltd. Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases
US8648177B2 (en) 2009-11-24 2014-02-11 Grifols Therapeutics Inc. Lyophilization methods, compositions, and kits

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940480A (en) * 1972-05-08 1976-02-24 Eisai Co., Ltd. Process for production of stabilized powdery secretin preparation by lyophilization
US20070020199A1 (en) * 1994-03-07 2007-01-25 Platz Robert M Dispersible macromolecule compositions and methods for their preparation and use
US20080261868A1 (en) * 1999-03-05 2008-10-23 Leland Shapiro Methods and Compositions for Treating Diabetes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566031B2 (en) * 2019-03-04 2023-01-31 Tae Life Sciences, Llc Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof

Also Published As

Publication number Publication date
EP2496246B1 (en) 2018-06-27
AU2010315325B2 (en) 2014-11-27
AU2010315325A1 (en) 2012-06-07
ES2679819T8 (es) 2019-01-22
WO2011056793A3 (en) 2011-09-29
CN102655876B (zh) 2015-07-15
BR112012010392B1 (pt) 2021-01-05
JP2015221835A (ja) 2015-12-10
WO2011056793A2 (en) 2011-05-12
CA2779369A1 (en) 2011-05-12
NZ599783A (en) 2013-10-25
RU2555332C2 (ru) 2015-07-10
CA2779369C (en) 2018-06-19
IL219485A0 (en) 2012-06-28
IL219485A (en) 2017-06-29
MX2012005132A (es) 2012-07-25
KR20120114235A (ko) 2012-10-16
EP2496246A4 (en) 2013-03-27
BR112012010392B8 (pt) 2021-05-25
JP6030201B2 (ja) 2016-11-24
CL2012001159A1 (es) 2012-09-14
CN102655876A (zh) 2012-09-05
US9616126B2 (en) 2017-04-11
JP2013510158A (ja) 2013-03-21
RU2012122793A (ru) 2013-12-10
TR201809898T4 (tr) 2018-07-23
PT2496246T (pt) 2018-07-31
US20160106843A1 (en) 2016-04-21
EP2496246A2 (en) 2012-09-12
PL2496246T3 (pl) 2018-09-28
HUE039240T2 (hu) 2018-12-28
ES2679819T3 (es) 2018-08-31
BR112012010392A2 (pt) 2016-07-12

Similar Documents

Publication Publication Date Title
US9616126B2 (en) Composition, method, and kit for alpha-1 proteinase inhibitor
ES2758827T3 (es) Formulaciones para enzimas lisosómicas
JP4635340B2 (ja) Ｈｇｆ凍結乾燥製剤
CN107249622B (zh) 包含纤溶酶原的药物组合物和其用途
WO1997002832A1 (fr) Preparations lyophilisees de hgf
JP4119407B2 (ja) 凍結乾燥されたアルブミン非含有の組換え人血液凝固第８因子製剤
US20230277636A1 (en) Composition comprising highly-concentrated alpha1 proteinase inhibitor and method for obtaining thereof
ES2375706T3 (es) Composiciones de alfa 1-antitripsina y métodos de tratamiento que usan tales composiciones.
WO2022132636A1 (en) High concentration formulations of anti-csf1 and anti-csf1r antibodies
CN114126584A (zh) 重组蛋白质稳定制剂
KR20110015552A (ko) 건조한 트랜스글루타미나제 조성물
RU2813136C1 (ru) Композиция, содержащая высококонцентрированный ингибитор альфа-1-протеиназы, и способ ее приготовления
RU2776108C2 (ru) Лиофилизированный состав на основе hgf
NZ755249A (en) Composition comprising highly-concentrated alpha-1 proteinase inhibitor and method for obtaining thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT, NEW YORK

Free format text: SECURITY AGREEMENT;ASSIGNORS:GRIFOLS INC.;GRIFOLS THERAPEUTICS INC.;GRIFOLS-CHIRON DIAGNOSTICS CORP.;REEL/FRAME:032367/0001

Effective date: 20140227

Owner name: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AG

Free format text: SECURITY AGREEMENT;ASSIGNORS:GRIFOLS INC.;GRIFOLS THERAPEUTICS INC.;GRIFOLS-CHIRON DIAGNOSTICS CORP.;REEL/FRAME:032367/0001

Effective date: 20140227

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: TALECRIS BIOTHERAPEUTICS, INC., CALIFORNIA

Free format text: RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 26390/0193;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH;REEL/FRAME:041494/0017

Effective date: 20140227

Owner name: GRIFOLS, S.A., SPAIN

Free format text: RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 26390/0193;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH;REEL/FRAME:041494/0017

Effective date: 20140227

Owner name: GRIFOLS INC., CALIFORNIA

Free format text: RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 26390/0193;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH;REEL/FRAME:041494/0017

Effective date: 20140227

AS Assignment

Owner name: GRIFOLS SHARED SERVICES NORTH AMERICA INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANK;REEL/FRAME:041638/0527

Effective date: 20170131

Owner name: GRIFOLS SHARED SERVICES NORTH AMERICA INC., CALIFO

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANK;REEL/FRAME:041638/0527

Effective date: 20170131

Owner name: GRIFOLS THERAPEUTICS INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANK;REEL/FRAME:041638/0527

Effective date: 20170131

Owner name: GRIFOLS DIAGNOSTIC SOLUTIONS INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANK;REEL/FRAME:041638/0527

Effective date: 20170131